CRBP
Corbus Pharmaceuticals Holdings Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.
Market Cap: 347 Million
Primary Exchange: NASDAQ
Website: https://www.corbuspharma.com/
Shares Outstanding: 10.3 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 2.348526707337502
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1803 trading days
From: 2017-03-20 To: 2023-04-14
Lowest Point:
Corbus up 3% premarket on positive lenabasum data in rare autoimmune disorders
via: SeekingAlpha at 2019-06-12 04:44:17:000
Corbus Pharmaceuticals (NASDAQ: CRBP ) perks up 3% premarket on light volume in response to longer term data on lenabasum in mid-stage studies in systemic sclerosis (SSc) and dermatomyositis (DM). The results are being presented at EULAR in Madrid. More news on: Corbus Pharma… read more...
Corbus up 3% premarket on positive lenabasum data in rare autoimmune disorders
via: SeekingAlpha at 2019-06-12 04:44:17:000
Corbus Pharmaceuticals (NASDAQ: CRBP ) perks up 3% premarket on light volume in response to longer term data on lenabasum in mid-stage studies in systemic sclerosis (SSc) and dermatomyositis (DM). The results are being presented at EULAR in Madrid. More news on: Corbus Pharma… read more...
Robbins Arroyo LLP: Corbus Pharmaceuticals Holdings, Inc. (CRBP) Sued for Misleading Shareholders
via: Business Wire at 2019-06-10 14:39:00:000
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between November 14, 2016 and Feb… read more...
Robbins Arroyo LLP: Corbus Pharmaceuticals Holdings, Inc. (CRBP) Sued for Misleading Shareholders
via: Business Wire at 2019-06-10 14:39:00:000
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between November 14, 2016 and Feb… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|